David J. Galbreath has received funding from the ESRC and AHRC. The new US president, Donald Trump, has only been in office for a few days, but he has already changed his tune on the war in ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.